Anti-CTLA4 mAbs

Ipilimumab

Stage III and Metastatic melanoma

Anti-PD-L1 mAbs

Atezolizumab

2nd line regiment for metastatic nonsmall-cell lung cancer Advanced or metastatic urothelial carcinoma

Avelumab

Advanced or metastatic urothelial carcinoma Metastatic Merkel cell carcinoma

Durvalumab

Advanced or metastatic urothelial carcinoma

Anti-PD-1 mAbs

Nivolumab

Metastatic melanoma

2nd line metastatic regiment of nonsmall-cell lung cancer

2nd line regiment of metastatic renal cell carcinoma

Refractory classical Hodgkin lymphoma

Recurrent or metastatic squamous cell carcinoma of the head and neck Advanced or metastatic urothelial carcinoma

Pembrolizumab

Metastatic melanoma

1st and 2nd line regiment for metastatic nonsmall-cell lung cancer Advanced or metastatic renal cell carcinoma Refractory classical Hodgkin lymphoma MSI-high or MMR-deficient metastatic solid tumors Advanced or metastatic urothelial carcinoma